EXTENDED RELEASE ORAL DRUG DELIVERY SYSTEM

1. Pfizer, Detrol® L.A. tolterodine tartrate extended release capsule, http://www.drugbank.ca/system/fda labels/ DB01036.pdf). Accessed October 2011.
2. Ehab Ahmed MH. Ph.D. Thesis: Application and evaluation of extended release technology to loop diuretics. University of Cincinnati (2002): 78-82..
3. Madhusudhan P and Nazeer S: Extended release formulation. International Journal of Pharmacy and Technology 2010; 2: 625¬684.
4. Donald Wise. Handbook of Pharmaceutical Controlled Release Technology, Marcel Dekker Inc, London, First Edition (2000) : 431-465.
5. Santus G and Baker R: Osmotic drug delivery, a review of the patent literature. Journal of Control Release 1995; 35: 1-21.
6. Alfred Martin. Physical Pharmacy, Physical Chemical Principles in the Pharmaceutical Sciences, Lea & Fabiger, Fourth Edition (1993): 532-536.
7. James McGinity. Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms,
Marcel Dekker Inc, Second Edition (1997): 1-474.
8. Bodmeier R: Tableting of coated pellets, review. Europian Journal of Pharmaceutics and Biopharmaceutics 1997; 43: 1-8.
9. Bechgaard H and Nielsen G: Controlled-release multiple-units and single-unit doses a literature review. Drug Development and Industrial Pharmacy 1978; 4: 53 - 67.
10. Ghebre-Sellassie. Multiparticulate Oral Drug Delivery, Marcel Dekker Inc, First
Edition (1997): 79-355.
11. Karrout Y, Neut C, Wils D and Siepmann F: Novel polymeric film coatings for colon targeting Drug release from coated pellets. Europian Journal of Pharmaceutical
Science 2009; 37: 427-433.
12. Pearnchob N. Ph.D. Thesis: Evaluation of new film coating processes and materials. University of Berlin (2002): 45-48.
13. Varshosaz J, Kennedy RA and Gipps EM: Use of enteric polymers for production of microspheres by extrusion-spheronization. Pharm Acta Helv 1997; 72:
145-152.
14. Bianchini R, Bruni G, Gazzaniga A and Vecchio C: Influence of extrusionspheronization processing on the physical properties of d-Indobufen pellets containing pH adjusters. Drug Development
and Industrial Pharmacy 1992; 18: 1485¬1503.
15. Glaessl B, Siepmann F, Tucker I and Siepmann J: Characterization of quaternary polymethacrylate films containing tartaric acid, metoprolol free base or metoprolol tartrate. Europian Journal of Pharmacy and Biopharmaceutics 2009; 73: 366-372.
16. Jenquin MR and McGinity JW:
Characterization of acrylic resin matrix films and mechanisms of drug-polymer interactions. International Journal of
Pharmceutics 1994; 101: 23-34.
17. Huang X and Brazel C: On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. Journal of Control Release 2001; 73: 121¬136.
18. Scott DC and Hollenbeck RG: Design and manufacture of a zero-order sustained-release pellet dosage form through non uniform drug distribution in a diffusional matrix. Pharmaceutical Research 1991; 8:
156-161.
ISSN: 2277-8713
IJPRBS
19. Rahman NU and Yuen KH: Eudragit
NE40-drug mixed coating system for controlling drug release of core pellets. Drug Development and Industrial Pharmacy 2005; 31: 339 -347.
20. Rahman NU, Yuen KH, Khan NA and
Woei WJ: Drug-polymer mixed coating: a new approach for controlling drug release rates in pellets. Pharmceutical Development
and Technology 2006; 11: 71-77.
21. Peppas N: Analysis of Fickian and non-Fickian drug release from polymers. Pharm
Acta Helv 1985; 60: 110-111.
22. Ritger P and Peppas N: A simple equation for description of solute release I, Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. Journal of
Control Release 1987; 5: 23-36.
23. Siepmann J and Siepmann F: Mathematical modeling of drug delivery. International. Journal of Pharmacy 2008;
364: 328-343.
24. Lippold BC and Monells PR: Control
and stability of drug release from diffusion pellets coated with the aqueous quaternary polymethacrylate dispersion Eudragit RS 30
D. Pharmazie 2001; 56: 477-483.25. Ozturk AG, Ozturk SS, Palsson BO and Dressman JB: Mechanism of release from pellets coated with an ethylcellulose-based film. Journal of Control Release 1990; 14: 203-213.
26. Munday DL and Fassihi AR: Controlled release delivery: Effect of coating composition on release characteristics of mini-tablets. International Journal of Pharmaceutics 1989; 52: 109-114.
27. Sadeghi F, Ford J and Rajabi-Siahboomi A: The influence of drug type on the release profiles from Surelease-coated pellets. International Journal of
Pharmaceutics 2003; 254: 123-135.
28. Kallai N, Luhn O, Dredan J and Antal I: Evaluation of drug release from coated pellets based on isomalt, sugar, and microcrystalline cellulose inert cores. AAPS Pharmaceutical Science Technology 1982;
11: 383-391.
29. Frohoff-Hulsmann MA, Lippold BC and McGinity JW: Aqueous ethyl cellulose dispersion containing plasticizers of different water solubility and hydroxypropyl methyl-cellulose as coating material for diffusion pellets II, properties of sprayed films. Europian Journal of Pharmaceutics and Biopharmaceutics 1999; 48: 67-75.
ISSN: 2277-8713
IJPRBS
30. Bodmeier R and Paeratakul O: Dry and wet strengths of polymeric films prepared from an aqueous colloidal polymer dispersion, Eudragit RS30D. International Journal of Pharmaceutics 1993; 96: 129-138.
31. Tang L, Schwartz J, Porter S and Wigent R: Drug release from film-coated chlorpheniramine maleate nonpareil beads, effect of water-soluble polymer, coating level, and soluble core material. Pharmaceutical Development and
Technology 2000; 5: 383-390.
32. Sadeghi F, Ford J and Rubinstein MH: Comparative Study of Drug Release from Pellets Coated with HPMC or Surelease. Drug Development and Industrial Pharmacy
2000; 26: 651-660.
33. Bodmeier R and Paeratakul O: Dry and wet strengths of polymeric films prepared from an aqueous colloidal polymer dispersion, Eudragit RS30D. International Journal of Pharmaceutics 1993; 96: 129-138.
34. Siepmann F, Siepmann J, Walther M, MacRae R and Bodmeier R: Blends of aqueous polymer dispersions used for pellet coating, Importance of the particle size. Journal of Control Release 2005; 105: 226¬239.35.
Bhattacharjy
a S and Wurster D: Investigation of the Drug Release and Surface Morphological Properties of Film-Coated Pellets, and Physical, Thermal and Mechanical Properties of Free Films as a Function of Various Curing Conditions. AAPS Pharmaceutical Science and Tecnology 2008; 9: 449-457.
36.
Li
n AY, Muhammad NA and Augsburger LL: A Study of the Effects of Curing and Storage Conditions on Controlled Release Diphenhydramine HCl Pellets Coated with Eudragit®NE30D. Pharmaceutical Development and Technology 2003; 8: 277 - 287.
37.
Williams-II
I RO and Liu J: Influence of processing and curing conditions on beads coated with an aqueous dispersion of cellulose acetate phthalate. Europian Journal of Pharmaceutics Biopharmaceutics 2000;
49: 243-252.
38.
Amigh
i K and Moes A: Influence of plasticizer concentration and storage conditions on the drug release rate from Eudragit RS 30D film-coated sustainedrelease theophylline pellets. Europian Journal of Pharmaceutics and Biopharmaceutics 1996; 42: 29-35.
ISSN: 2277-8713
IJPRBS
39. Yang QW, Flament MP, Siepmann F,
Herry C and Tchoreloff P: Curing of aqueous polymeric film coatings: Importance of the coating level and type of plasticizer. Europian Journal of Pharmaceutics and Biopharmaceutics 2010;
74: 362-370.
40. Siepmann F, Siepmann J, Walther M, MacRae R and Bodmeier R: Aqueous HPMCAS coatings Effects of formulation and processing parameters on drug release and mass transport mechanisms. Europian Journal of Pharmaceutics and Biopharmaceutics 2006; 63: 262-269.
41. Wu C and McGinity J: Influence of relative humidity on the mechanical and drug release properties of theophylline pellets coated with an acrylic polymer containing methylparaben as a non-traditional plasticizer. Europian Journal of Pharmaceutics and Biopharmaceutics 2000;
50: 277-284.
42. Liu J and Williams R: Properties of heat-humidity cured cellulose acetate phthalate free films. Europian Journal of Pharmaceutical Science 2002; 17: 31-41.
43. Kranz H and Gutsche S: Evaluation of the drug release patterns and long term stability of aqueous and organic coatedpellets by using blends of enteric and gastrointestinal insoluble polymers. International journal of Pharmaceutics 2009;
380: 112-119.
44. Azarmi S, Roa W and Lobenberg R: Current perspectives in dissolution testing of conventional and novel dosage forms. International Journal of Pharmaceutics 2007;
328: 12-21.
45. Gu CH, Gandhi RB, Tay LK and
Raghavan K: Importance of using physiologically relevant volume of dissolution medium to correlate the oral exposure of formulations of BMS-480188 mesylate." International Journal of
Pharmaceutics 2004; 269: 195-202.
46. Royce A, Li S, Weaver M and Shah U:
In vivo and in vitro evaluation of three controlled release principles of 6-N-cyclohexyl-2'-O-methyladenosine. Journal
of. Control Release 2004; 97: 79-90.
47. Qureshi SA: Developing discriminatory drug dissolution tests and profiles: some thoughts for consideration on the concept and its interpretation. Dissolution
Technology 2006; 13: 18-23.
ISSN: 2277-8713
IJPRBS
48. Emami J: In vitro - in vivo correlation: from theory to applications. Journal of Pharmaceutical Science 2006; 9: 169-189.
49. Food and Drug Administration (FDA), Center for Drug Evaluation and Research
(CDER), Guidance for Industry, SUPAC-
MR: Modified Release Solid Oral Dosage Forms,
http://www.fda.gov/downloads/Drugs/Guida nceComplianceRegulatoryInformati on/Guidances/ucm070640.pdf). Accessed November 2011.
50. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Guidance for Industry, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, (http://www.fda.gov/downloads/drugs/guida ncecomplianceregulatoryinformation /guidances/ucm070246.pdf). Accessed November 2011.
51. Dressman JB, Amidon GL and Shah VP: Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharmaceutical Research
1998; 15: 11-22.52. Schiller C, Frohlich C, Giessmann T, Siegmund W and Weitschies W: Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacology and Therapeutics
2005; 22: 971-979.
53. Ibekwe VC, Fadda HM, McConnell EL, Khela MK and Basit AW: Interplay
Between Intestinal pH, Transit Time and Feed Status on the In Vivo Performance of pH Responsive Ileo-Colonic Release Systems. Pharmaceutical Research 2008; 25:
1828-1835.
54. Kalantzi L, Goumas K, Kalioras V, Abrahamsson B and Reppas C: Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharmaceutical Research 2006; 23:
165-176.
55. TenHoor C, Bakatselou V and Dressman J: Solubility of mefenamic acid under simulated fed- and fasted-state conditions. Pharmaceutical Research 1991;
8: 1203-1205.
56. Kostewicz ES, Brauns U, Becker R and Dressman J: Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in
ISSN: 2277-8713
IJPRBS
biorelevant media. Pharmaceutical Research
2002; 19: 345-349.
57. Khan MZ: Dissolution testing for sustained or controlled release oral dosage forms and correlation with in vivo data, Challenges and opportunities. International Journal of Pharmaceutics 1996; 140: 131¬143.
58. Marvola M, Kannikoski A, Aito H and
Nykanen S: The effect of food on gastrointestinal transit and drug absorption of a multi particular sustained-release verapamil formulation. International Journal of Pharmaceutics 1989; 53: 145-155.
59. Kenyon C, Hooper G, Tierney D, Butler J, Devane J and Wilding I: The effect of food on the gastrointestinal transit and systemic absorption of naproxen 107 from a novel sustained release formulation. Journal of Control Release 1995; 34: 31-36.
60. Fabre LF and Timmer CJ: Effects of food on the bioavailability of gepirone from extended-release tablets in humans, results of two open-label crossover studies. Current
Therapeutic Research 2003; 64: 580-598.
61. Developing Dissolution Tests for Modified Release Dosage Forms, General Considerations,(http://www.dissolutiontech.com/DTresour/ 299articles/299Crison.htm). Accessed October 2011.
ISSN: 2277-8713
IJPRBS
62. Porter CJ and Charman WN: In vitro
assessmen
t of oral lipid based formulations. Advanced Drug Delivery Review 2001; 50: S127-S147.